| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184833 | Gynecologic Oncology | 2015 | 6 Pages |
Abstract
Oral etoposide and intravenous irinotecan had a moderate RR but did not meet the primary endpoint. Because of toxicity, we do not recommend this regimen outside of clinical trials. In particular, when considering this regimen for elderly patients, extreme caution is advised.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Koji Matsumoto, Noriyuki Katsumata, Taro Shibata, Toyomi Satoh, Motoaki Saitou, Mayu Yunokawa, Tadao Takano, Kenichi Nakamura, Toshiharu Kamura, Ikuo Konishi,